Hongda High-Tech Holding (002144.SZ) issued a profit warning that the net profit for the year 2024 is expected to decrease by 65.96% to 73.25% to 22 million to 28 million yuan.
Hongda Gaoke (002144.SZ) released its performance forecast for 2024, expecting full-year net profit attributable to the company's shareholders ...
Hongda High-Tech Holding (002144.SZ) has released its performance forecast for the year 2024, with an expected net profit attributable to shareholders of the listed company of 22 million to 28 million yuan, a year-on-year decrease of 65.96% to 73.25%.
During the reporting period, the company's two main businesses of fabric manufacturing and medical equipment operated normally, with both operating income and net profit from the main business showing growth. The sales volume of the company's automotive interior fabrics and functional clothing fabrics increased steadily, with the company's operating income increasing by about 20% year-on-year, and the gross profit margin remaining stable. At the same time, the company increased its investment in product development and market expansion for its subsidiary Zhejiang Wilde Smart Medical Technology Co., Ltd., resulting in a decrease in the net profit of the company's medical equipment industry. During the reporting period, Zhejiang Wilde obtained three medical device registration certificates and successfully developed the intelligent massage Siasun Robot & Automation and "AI Huiying" series of color ultrasound diagnostic equipment, gradually establishing a stable sales team and distribution network.
Related Articles

New Stock News | Jingfeng Medical has passed the hearing of the Hong Kong Stock Exchange and is committed to designing, developing, and manufacturing surgery Siasun Robot&Automation.
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange

JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
New Stock News | Jingfeng Medical has passed the hearing of the Hong Kong Stock Exchange and is committed to designing, developing, and manufacturing surgery Siasun Robot&Automation.

IPO news | Keen Gene submits application to Hong Kong Stock Exchange
.png)
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.






